Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.7    
    

 
 

EMPLOYMENT AGREEMENT    
    

        THIS AGREEMENT is made and entered into by and between Myriad Genetics, Inc. and its wholly-owned subsidiary, Myriad Genetic Laboratories, Inc.
(hereinafter collectively referred to as "Company'), AND Gregory C. Critchfield (hereinafter referred to as "Employee"). 

        In
consideration of the undersigned's employment, compensation, and other valuable consideration and mutual covenants contained herein, the parties agree as follows: 

        1.    At Will Employment.    Company employs Employee on an at-will basis, which means that either
Employee or the Company can terminate the employment relationship at any time for any reason, with or without notice or cause. Employee's employment with the Company is not for any particular period
of time. No manager or supervisor of the Company has authority to modify or alter the Company's at-will employment relationship with Employee, and any statements or promises contrary to at
will employment may not be relied upon by Employee. Employee's at-will employment with the Company may not be modified or changed in any way, except through a new written employment
agreement signed by the President and CEO of the Company and Employee. 

        2.    Compensation.    Company initially shall pay Employee in full for Employee's services hereunder at the rate of
$225,000 per year, commencing on the 15th day of September, 1998. 

        3.    Duties.    Employee shall at all times faithfully, industriously, and to the best of his/her ability,
experience, and talents, perform all of the duties that may be required of him/her pursuant to the express and implicit terms hereof, to the reasonable satisfaction of the Company. Employee shall not
directly or indirectly, in any manner or in any capacity, engage in an outside business endeavor of any kind without the Company's expressed written approval, signed by an officer of the Company. 

        4.    Inventions or Improvements.    Any inventions, discoveries, know-how, or improvements, which
Employee may conceive, make, invent, or develop during his/her employment by the Company, relating to any matter or thing, including but not limited to genetic maps, genes, gene sequences, material
containing a DNA sequence, gene products, protein molecules, nucleic acid molecules, monoclonal antibodies, pedigrees, genealogy data, germplasm, bacterial artificial chromosomes (BACs), contigs, cell
lines, microorganisms, biologically active compounds, processes, and methods of gene identification or gene sequencing that may be connected in any way with Employee's work or related in any way to
Company's business or future business, shall be the absolute property of the Company and shall be promptly disclosed to the Company by Employee. Employee agrees that he/she will, at the request of the
Company, at any time during the employment or thereafter, assign to the Company the rights to said inventions and improvements and any patent applications filed or patents granted thereon. 

        5.    Nondisclosure of Information.    Employee agrees that during his/her employment and thereafter, he/she will not
reveal to any person, agency, company, business, or organization, unless authorized by Company, any confidential or proprietary information concerning Company, including but not limited to any
inventions, discoveries, know-how, improvements, processes, products, services, proposals, solicitations, negotiations, customers, manner and method of operations, trade secrets, and the
like. 

        6.    Noncompetition Agreement.    Employee agrees that during the term of his/her employment he/she will not compete
with Company either directly or indirectly in any area in which, during the term of his/her employment, Company does business or reasonably contemplates that it will do business in the reasonably
foreseeable future. Employee agrees that he/she will not use Company's name, facilities, confidential material, trade secrets, know-how, or privileged information to solicit from any
agency, company, business, or organization, work that would result in income or compensation of any form to Employee or another company or business organization. 

        7.    Construction.    The parties hereto agree that the terms of this Agreement shall be construed in accordance with
the laws of the State of Utah. 

 

        8.    Severability.    If any provisions hereof should be held invalid, illegal, or unenforceable in any respect in
any jurisdiction, then, to the fullest extent permitted by law, all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to
carry out the intentions of the parties hereto as nearly as may be possible. To the extent permitted by applicable law,
the parties hereto hereby waive any provision of law that would render any provisions hereof prohibited or unenforceable in any respect. 

        9.    Entire Agreement.    The parties agree that neither party has made any covenants not set forth herein, and that
this Agreement constitutes the entire agreement between the parties. No modification or amendment of this Agreement shall be effective unless made in writing and signed by Employee and Company. The
offer letter dated June 3, 1998 is attached here to and made a part of this agreement. 

        IN
WITNESS WHEREOF, the parties hereto have executed this Agreement on this 14th day of September, 1998. 

	EMPLOYEE:	 	COMPANY:
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	By:	 	/s/  GREGORY C. CRITCHFIELD      
	 	By:	 	/s/  PETER D. MELDRUM      

	 	 	 	 	 	 	 
	Position:  President, Myriad Genetic Laboratories	 	Title:  President & CEO

2

 

Offer Letter  

June 30,
1998 

Gregory
C. Critchfield, M.D., M.S.

11907 Autumn Ridge Drive

Sandy, UT 84092 

Dear
Greg, 

        On
behalf of all of the officers and research directors of Myriad Genetics, Inc., it has been a pleasure meeting with you. We were all impressed with you as a person, and with
your medical and diagnostic background and experience. We are confident that you will find Myriad to have the stimulating and rewarding environment that you seek. 

        Myriad
is pleased to offer you a position as President of Myriad Genetic Laboratories, Inc. at a base salary of $225,000. You will report directly to me, and your responsibilities
will be those described to you during our previous discussions. Additionally, you will be a member of Myriad's Executive Committee which is responsible for the formulation and implementation of
Myriad's corporate strategy. In addition to your base salary, you will be eligible to receive a cash bonus of up to one-third of your salary based upon your performance as determined by
the Board of Directors. We anticipate your start date to be August 3, 1998. 

        This
offer includes stock options in Myriad Genetics, Inc. representing 80,000 shares of common stock. The exercise price shall be determined by the Board of Directors after you
have accepted this offer. The exercise term is for a period of ten years. The stock option shares are subject to five year vesting (16,000 shares per year). 

        As
part of this offer, you will be eligible for Myriad's complete benefit program, including our excellent medical insurance, dental insurance, life/AD&D and long term disability
insurance, Section 125 cafeteria plan, and 401(k) retirement plan in which Myriad matches 50% of your contributions up to a maximum of 4% of your base salary. Also included is the Company's 12
paid holidays and 5 weeks of personal leave per year. 

        When
you report to work, you will be provided with more detailed information regarding our complete policies and benefits program. In the meantime, any questions regarding policies,
benefits administration, or eligibility may be directed to me at, 801-584-3634. 

        Myriad
is committed to maintaining its leadership position in the genomics field and to commercializing diagnostic and therapeutic products for major common diseases. Our success depends
upon bright, dedicated staff such as yourself. 

3

 

        Please
call me if you would like to discuss this offer further. If you are in agreement with the terms of this letter, please sign below and return one of these originals to my office as
soon as possible. I look forward to hearing your favorable response. 

	Very truly yours,	 	 
	 	 	 
	/s/  PETER D. MELDRUM      
 Peter D. Meldrum

President and CEO	 	 
	 	 	 
	PDM/bb	 	 
	 	 	 
	Accepted by:	 	 
	 	 	 
	/s/  GREGORY C. CRITCHFIELD      
	 	 
	 	 	 
	Date: July 27, 1998	 	 

4

QuickLinks

Exhibit 10.7

EMPLOYMENT AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.8    
    

 
 

EMPLOYMENT AGREEMENT    
    

        This Employment Agreement (the "Agreement") is entered into as of the 30th day of September, 1998, by and between Myriad Genetics, Inc. ("Myriad") and its
wholly owned subsidiary, Myriad Pharmaceuticals, Inc. ("Pharmaceuticals") and Adrian Norman Hobden, Ph.D. (The "Executive"). 

        In
consideration of the mutual promises contained herein, the parties hereto agree as follows: 

        1.    Employment.    Subject to the terms and conditions of this Agreement, Myriad hereby employs Executive on an
at-will basis as President of Pharmaceuticals, member of the Board of Directors of Pharmaceuticals, and member of the Executive Officers Committee of Myriad, and Executive hereby accepts
such employment beginning October 12, 1998 (the "Commencement Date"). 

        2.    Duties of Employment.    As the President of Pharmaceuticals, Executive shall at all times faithfully,
industriously, and to the best of his ability, experience, and talents, perform such duties as are customary and as may be required by such position, or as are assigned to Executive by the President
of Myriad or the Board of Directors of Pharmaceuticals from time to time and which are consistent with the duties of such position. In his capacity as President of Pharmaceuticals all employees of
Pharmaceuticals shall report to Executive. Executive shall devote his entire business time, ability and attention to the business of Myriad and Pharmaceuticals during the term of this Agreement.
Notwithstanding the foregoing, Executive shall not directly or indirectly render any services to other persons or entities of a business, commercial or professional nature which will in any way
interfere with the duties of Executive under this Agreement without the prior written approval of the Board of Directors of Myriad, which approval shall not be unreasonably withheld. The Executive's
services shall be performed primarily at Pharmaceuticals' principal executive offices at 320 Wakara Way, Salt Lake City, Utah. The parties acknowledge, however, that the Executive may be required to
travel in connection with the performance of his duties hereunder. 

        3.    Compensation.    

        3.1    Salary and Bonus.    Executive shall receive a base salary of $200,000 per annum, payable twice monthly in
equal installments. Executive shall also be entitled to a cash bonus on July 1, 1999 (and annually thereafter). The exact amount of such bonus shall be determined by the Myriad Board of
Directors based upon performance goals and milestones to be set annually by Executive and the Myriad Board of Directors. Executive's base salary shall be increased annually by the Myriad Board of
Directors, such adjustment to be determined in the Myriad Board's sole discretion. 

        3.2    Myriad Stock Options.    Following commencement of Executive's employment, Executive shall receive stock
options for 80,000 shares of Myriad Common Stock (the "Options") at the fair market value in accordance with the terms and conditions of 1992 Employee, Director and Consultant Stock Options Plan. Such
Options will be Incentive Stock Options to the extent allowed by law. Such Options will be subject to a five-year vesting provision based upon Executive's continued employment with Myriad
and Pharmaceuticals such that 1/60th of the underlying shares of the Options (1,333 shares) shall vest each month after commencement of Executive's employment. The unvested balance of Executive's
Options shall be forfeited upon any termination or cessation of Executive's employment except as set forth in Section 5.3 below. The Options term will be ten (10) years. In addition,
Myriad annually grants options to key employees based on their performance during the past fiscal year, the amount of such options to be determined in the Myriad Board's sole discretion. 

        3.3    Pharmaceuticals Stock Options.    Following commencement of Executive's employment, Executive shall receive
stock options for 120 shares which represents four percent (4%) of the issue and outstanding shares of Pharmaceuticals Common Stock ("the Pharmaceuticals Options") at $3,333.33 per share. Such
Pharmaceuticals Options will be Incentive Stock Options to the extent 

 

allowed
by law. Such Pharmaceuticals Options will be subject to a five-year vesting provision based upon Executive's continued employment with Myriad and Pharmaceuticals such that 1/60th
of the underlying shares of the Pharmaceuticals Options (2 shares) shall vest each month after commencement of Executive's employment. The unvested balance of Executive's Pharmaceuticals Options shall
be forfeited upon any termination or cessation of Executive's employment except as set forth in Section 5.3 below. The Pharmaceuticals Options term will be ten (10) years. Such
Pharmaceuticals Options may be converted into Myriad Common Stock in accordance with the terms and conditions of the 1998 Myriad Pharmaceuticals, Inc. Employee Stock Options Plan. 

        3.4    Relocation Expenses.    Myriad will reimburse the Executive for reasonable out-of pocket costs
(against documented receipts therefor) for (a) travel, meals and lodging in connection with a trip to Salt Lake City, Utah for the purpose of seeking a principal residence; (b) moving
expenses associated with the relocation of Executive and his family to the Salt Lake City area (including the shipping of household goods and automobiles from North Carolina and/or the United
Kingdom); (c) travel between
North Carolina and Salt Lake City; (d) reasonable legal and other fees associated with purchasing a home in the Salt Lake City area; and (e) temporary living expenses for Executive's
family for a period of 30 days. 

        3.5    Benefits.    Executive will be entitled to receive Myriad's standard benefits (medical insurance and dental
insurance) and participate in Myriad's 401(k) pension plan, life insurance/AD&D plan, short-term disability plan, long-term disability plan (which plan shall provide for annual
long-term disability benefits of approximately two-thirds of Executive's current base salary), Section 125 cafeteria plan, twelve paid holiday days, five weeks paid
personal days, and other benefits offered to Myriad officers generally. The Executive's total paid personal days shall increase by five days for each ten years of continuous employment with Myriad. 

        3.6    Green Card.    Myriad will sponsor and pay all costs associated with acquiring a "green card" for Executive and
his family. If Myriad is not successful in obtaining a "green card" for Executive which would enable Executive to continue his employment in the United States at Myriad or Pharmaceuticals and
Executive's employment is terminated at Myriad or Pharmaceuticals because Executive is forced to leave the United States, Executive's termination will be considered a termination not for cause and the
terms and conditions of Section 5.1(b) below shall apply. 

        4.    Proprietary Information and Inventions.    Executive agrees that all work products, discoveries, and inventions
which he may develop during the course of his employment with Pharmaceuticals and Myriad and all of the results therefrom, shall remain the sole property of Pharmaceuticals or Myriad respectively.
Executive agrees that as a condition of employment he will sign and abide by Myriad's standard form of proprietary information and assignment of inventions agreement, attached hereto as
Exhibit A (the "Proprietary Information Agreement") and incorporated herein by reference. Such agreement will continue in full force and effect throughout the period of Executive's employment
and shall survive any termination hereof. This Section 4 will survive any termination of this Agreement. 

        5.    Term and Termination.    

        5.1    Termination by Pharmaceuticals    

        (a)    Termination for Cause.    Myriad and Pharmaceuticals may terminate this Agreement at any time without prior
notice in its sole discretion, by reason of Executive's (i) breach of any material term of this Agreement, which breach is not cured within 60 days after written notice to Executive of
the existence of such breach, (ii) conviction of a misdemeanor or felony, excluding traffic and other minor violations, (iii) fraud, (iv) repeated unexplained or unjustified
absence or tardiness, after written notice thereof has been provided to Executive, (v) breach of fiduciary duty under applicable laws, this Agreement or Myriad policies or 

2

 

(vi) negligence
or misconduct where such negligence or misconduct has resulted or is likely to result in material damage to Myriad or its subsidiaries. Except for the actions which are set
forth in Section 5.1(a) above, termination for performance related reasons shall be deemed to be a termination not for cause pursuant to Section 5.1(b) below. Upon termination of
Executive's employment pursuant to this Section 5.1(a) any unvested Options or Pharmaceuticals Options held by Executive shall be subject to forfeiture in accordance with terms and conditions
of the applicable Plan, unless otherwise agreed to by the parties. 

        (b)    Termination Not for Cause.    Myriad shall also be entitled to terminate this Agreement at any time without any
reason or cause whatsoever; provided however, that in the event of a termination of this Agreement without cause pursuant to this Section 5.1(b)
Myriad shall pay to Executive his base salary at the time of such termination for the period of 9 months (12 months if Executive has been with Myriad for over 5 years) following
such termination. Amounts payable to Executive under this Section 5.1(b) (the "Severance Payments") shall be payable twice monthly in equal installments. Upon termination of Executive's
employment pursuant to this section 5.1(b) any unvested Options or Pharmaceuticals Options held by Executive shall be subject to forfeiture in accordance with terms and conditions of the
applicable Plan, unless otherwise agreed to by the parties. 

        5.2    Termination by Executive.    Executive may terminate this Agreement upon 30 days prior written notice to
Myriad at any time without reason or cause whatsoever; provided however, that upon any termination of Executive's employment pursuant to this
Section 5.2, (i) Executive shall not be entitled to receive Severance Payments pursuant to Section 5.1(b) above, and (ii) any unvested Options or Pharmaceuticals Options
held by Executive shall be subject to forfeiture in accordance with terms and conditions of the applicable Plan, unless otherwise agreed to by the parties. 

        5.3    Change of Control.    

        (a)    Termination or Reduction of Duties.    If Myriad or Pharmaceuticals is to be consolidated with or acquired by
another entity in a merger, sale of all or substantially all of Myriad's or Pharmaceuticals' assets or otherwise ("Acquisition") and if as a result of such Acquisition Executive's duties and
responsibilities are substantially reduced or eliminated, then Executive may terminate this Agreement upon 60 days written notice to Myriad, if Executive's duties and responsibilities are not
reinstated to substantially the same level as prior to such Acquisition in a new position in Myriad or
Pharmaceuticals. In the event of termination by Executive pursuant to this Section 5.3(a), Myriad shall pay to Executive his base salary for a period of 12 months at the time of such
termination. 

        (b)    Options Adjustments.    Immediately prior to the consummation of an Acquisition, Executive's Options and
Pharmaceuticals Options shall as determined by the Myriad Board of Directors, either (i) become fully vested and must be exercised prior to completion of such Acquisition; or
(ii) terminate in exchange for a cash payment equal to the excess of the fair market value of such Options and/or Pharmaceuticals Options (vested and unvested over the exercise price thereof);
or (iii) continue by substituting on an equitable basis for the shares subject to such Options and Pharmaceuticals Options the consideration payable with respect to the outstanding shares of
Common Stock in connection with the Acquisition in accordance with the terms and conditions of the applicable Plan. 

        6.    Miscellaneous.    

        6.1    Governing Law.    This Agreement and all acts and transactions pursuant hereto and the rights and obligations
of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Utah, without reference to rules of conflict of law or 

3

 

statutory
arbitration. The venue for the enforcement of any arbitrator's decision regarding any controversy under this Agreement shall be in the federal or state courts in the location of the
arbitration proceeding as set forth in Section 6.2 below, and each party submits to the personal jurisdiction of such courts. Service of process shall be effected by registered mail sent to the
address below. 

        6.2    Dispute Resolution.    Any controversy between the parties involving enforcement, construction or application
of any term, provision, or condition of this Agreement, shall be submitted for final and binding arbitration in the location within the U.S. where the non moving party is located (or in Salt Lake
City, Utah, if Executive is not residing in the U.S.) in accordance with the rules of the American Arbitration Association. Subject to Section 6.3 below, the costs of the arbitrator will be
borne by the losing party. The arbitrator(s) shall apply Utah law, without reference to rules of conflict of law or statutory rules of arbitration, to the merits of any dispute or claim. Judgment on
the award rendered by the arbitrator(s) may be entered in any court having competent jurisdiction. 

        6.3    Remedies.    The parties to this Agreement acknowledge that any breach of Executive's obligations under
Section 4 is likely to cause or threaten irreparable harm to Myriad and Pharmaceuticals and, accordingly, each party agrees that in such event, Myriad and Pharmaceuticals shall be entitled to
equitable relief to protect its interest therein, including but not limited to preliminary and permanent injunctive or mandatory relief, as well as money damages. This Section 6.3 shall survive
any termination of this Agreement. 

        6.4    Assignment.    Since this Agreement is based upon the unique abilities and personal relationship of Executive,
he will have no right to assign this Agreement or any of his rights hereunder without the written consent of Myriad, and Myriad will have no right to assign any of its rights hereunder except to a
successor in interest of Myriad. Subject to the foregoing, this Agreement will inure to the benefit of and will be binding upon the successors and assigns of Myriad. 

        6.5    Entire Agreement.    This Agreement and the exhibits hereto set forth the entire Agreement and understanding of
the parties relating to its subject matter and merges all prior discussions and agreements between them. No modification or amendment to this Agreement, nor any waiver of any rights under this
Agreement, will be effective unless in writing signed by both parties. 

        6.6    Severability.    If any provision of this Agreement is found invalid or unenforceable, that provision will be
enforced to the maximum extent permissible under applicable law, and the remaining provisions of this Agreement will stay in force. In addition, the parties agree to negotiate in good faith a
provision to replace the provision found invalid or unenforceable that will have, to the extent possible, the same economic effect. 

        6.7    Notices.    Any notice required or permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the party to be notified at the address indicated for such party below, or at such other address as such party may designate to the other parties. 

        6.8    Titles and Subtitles.    The titles and subtitles used in the Agreement are used for convenience only and are
not to be considered in construing or interpreting this Agreement. 

        6.9    Counterparts.    This Agreement may be executed in tow or more counterparts, each of which shall be deemed an
original and all of which together shall constitute one instrument. 

4

 

        6.10    Guarantee.    All obligations of Pharmaceuticals will be guaranteed by Myriad. 

        IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written. 

	MYRIAD GENETICS, INC.	 	ADRIAN NORMAN HOBDEN, PH.D.
	 	 	 	 	 
	By:	/s/  PETER D. MELDRUM      
	 	By:	/s/  ADRIAN N. HOBDEN      

	 	 	 	 	 
	Title:	President and CEO	 	 	 
	 	 	 	 	 
	Address:	320 Wakara Way

Salt Lake City, Utah 84108	 	Address:	1609 Cedar Lane

Raleigh, NC 27614
	 	 	 	 	 
	MYRIAD PHARMACEUTICALS, INC.	 	 	 
	 	 	 	 	 
	By:	/s/  PETER D. MELDRUM      
	 	 	 
	 	 	 	 	 
	Title:	Chairman	 	 	 
	 	 	 	 	 
	Address:	320 Wakara Way

Salt Lake City, Utah 84108	 	 	 

5

  

 
 

Exhibit A    
    

 
  PROPRIETARY INFORMATION AGREEMENT    
    

        THIS AGREEMENT is made and entered into by and between Myriad Genetics, Inc. and its wholly-owned subsidiary, Myriad Pharmaceuticals, Inc.,
(hereinafter collectively referred to as "Company"), and Adrian Norman Hobden, (hereinafter referred to as "Employee"). 

        In
consideration of the undersigned's employment, compensation, and other valuable consideration and mutual covenants contained herein, the parties agree as follows: 

        1.    Duties.    Employee shall at all times faithfully, industriously, and to the best of his/her ability,
experience, and talents, perform all of the duties that may be required of him/her pursuant to the express and implicit terms hereof, to the reasonable satisfaction of the Company. 

        2.    Inventions or Improvements.    Any inventions, discoveries, know-how, or improvements, which
Employee may conceive, make, invent, or develop during his/her employment by the Company, relating to any matter or thing, including but not limited to genetic maps, genes, gene sequences, material
containing a DNA sequence, gene products, protein molecules, nucleic acid molecules, monoclonal antibodies, pedigrees, genealogy data, germplasm, yeast artificial chromosomes (YACs), contigs, cell
lines, microorganisms, biologically active compounds, processes, and methods of gene identification or gene sequencing that may be connected in any way with Employee's work or related in any way to
Company's business or future business, shall be the absolute property of the Company and shall be promptly disclosed to the Company by Employee. For the consideration of above-mentioned, Employee
agrees that he/she will, at the request of the Company, at any time during the employment or thereafter, assign to the Company the rights to said inventions and improvements and any patent
applications filed or patents granted thereon. 

        3.    Nondisclosure of Information.    Employee agrees that during his/her employment and thereafter, he/she will not
reveal to any person, agency, company, business, or organization, unless authorized by Company, any confidential information concerning Company, including but not limited to any inventions,
discoveries, know-how, improvements, processes, products, services, proposals, solicitations, negotiation, customers, manner and method of operations, trade secrets, and the like. 

        4.    Noncompetition Agreement.    Employee agrees that during the term of his/her employment he/she will not compete
with Company either directly or indirectly in any area in which, during the tour of his/her employment, Company does business or reasonably contemplates that it will do business in the reasonably
foreseeable future. Employee agrees that he/she will not use Company's name, facilities, confidential material, trade secrets, know-how, or privileged information to solicit from any
agency, company, business, or organization, work that at a later time would result in Compensation of any form for Employee or another company or business organization. 

        5.    Construction.    The parties hereto agree that the terms of this Agreement shall be construed in accordance with
the laws of the State of Utah. 

        6.    Severability.    If any provisions hereof should be held invalid, illegal or unenforceable in any respect in any
jurisdiction, then, to the fullest extent permitted by law, all other provision hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out
the intentions of the parties hereto as nearly as may be possible. To the extent permitted by applicable law, the parties hereto hereby waive any provision of law that would render any provisions
hereof prohibited or unenforceable in any respect. 

        IN
WITNESS WHEREOF, the parties hereto have executes this Agreement of this 30th day of September, 1998. 

6

QuickLinks

Exhibit 10.8

EMPLOYMENT AGREEMENT

Exhibit A

PROPRIETARY INFORMATION AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}]]